Nothing Special   »   [go: up one dir, main page]

NO20081415L - Fremgangsmate for utforelse av en perkutan koronar intervensjon - Google Patents

Fremgangsmate for utforelse av en perkutan koronar intervensjon

Info

Publication number
NO20081415L
NO20081415L NO20081415A NO20081415A NO20081415L NO 20081415 L NO20081415 L NO 20081415L NO 20081415 A NO20081415 A NO 20081415A NO 20081415 A NO20081415 A NO 20081415A NO 20081415 L NO20081415 L NO 20081415L
Authority
NO
Norway
Prior art keywords
percutaneous coronary
coronary intervention
patient
procedure
methods
Prior art date
Application number
NO20081415A
Other languages
English (en)
Inventor
Marie France Bregeault
Flavia Dietrich-Neto
Gilles Montalescot
Phillipe Gabriel Steg
Luis O Toro-Gigueroa
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20081415L publication Critical patent/NO20081415L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fremgangsmåter for utførelse av en perkutan koronar intervensjon i en pasient med behov derav som omfatter administrering av intravenøs bolus som omfatter en effektiv mengde av enoksaparinnatrium til pasienten etter kappeinsersjon og før perkutan koronar intervensjon her beskrevet. Også beskrevet er fremgangsmåter for forhindring eller behandling av trombose, slik som trombotiske episoder, i en human perkutan koronar intervensjonspasient med behandling av pasienten med enoksaparin.
NO20081415A 2005-09-02 2008-03-18 Fremgangsmate for utforelse av en perkutan koronar intervensjon NO20081415L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71332905P 2005-09-02 2005-09-02
PCT/IB2006/003673 WO2007026265A2 (en) 2005-09-02 2006-09-04 Use of enoxaparin for performimg percutaneous coronary intervention

Publications (1)

Publication Number Publication Date
NO20081415L true NO20081415L (no) 2008-03-18

Family

ID=37809254

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081415A NO20081415L (no) 2005-09-02 2008-03-18 Fremgangsmate for utforelse av en perkutan koronar intervensjon

Country Status (13)

Country Link
US (1) US20070191304A1 (no)
EP (1) EP1940400A2 (no)
JP (1) JP2010502560A (no)
KR (1) KR20080063467A (no)
CN (1) CN101277693A (no)
AU (1) AU2006286244A1 (no)
BR (1) BRPI0616295A2 (no)
CA (1) CA2620255A1 (no)
MA (1) MA31719B1 (no)
NO (1) NO20081415L (no)
RU (1) RU2008112667A (no)
WO (1) WO2007026265A2 (no)
ZA (1) ZA200801226B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236405A1 (en) * 2008-07-29 2011-09-29 Tel Hashomer Medical Research Infrastructure And Services Ltd. Coagulation factor modulation for controlling transplant organ size
CN102050888B (zh) * 2010-12-13 2011-12-07 河北常山生化药业股份有限公司 一种依诺肝素钠的制备方法
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist

Also Published As

Publication number Publication date
RU2008112667A (ru) 2009-10-10
KR20080063467A (ko) 2008-07-04
CA2620255A1 (en) 2007-03-08
BRPI0616295A2 (pt) 2011-06-14
JP2010502560A (ja) 2010-01-28
WO2007026265A3 (en) 2007-09-27
EP1940400A2 (en) 2008-07-09
AU2006286244A1 (en) 2007-03-08
MA31719B1 (fr) 2010-10-01
CN101277693A (zh) 2008-10-01
ZA200801226B (en) 2008-12-31
US20070191304A1 (en) 2007-08-16
WO2007026265A2 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
NO20083722L (no) Immunogen sammensetning
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
TW200503751A (en) Methods for treating sinus headache
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
MA33043B1 (fr) Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
NO20070330L (no) Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser
ECSP13012661A (es) Composición farmacéutica, métodos de tratamiento y usos de la misma.
HK1125287A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
NO20065453L (no) Fenoksyalkykarboksylsyrederivater i behandlingen av inflammatoriske sykdommer.
BR112012006468A2 (pt) métodos de tratamento de inflamação
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX2020001342A (es) Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
NO20081415L (no) Fremgangsmate for utforelse av en perkutan koronar intervensjon
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
MX2009004142A (es) Metodo para prevenir o tratar sindrome metabolico.
BRPI0509876A (pt) métodos para controlar a angiogênese e a proliferação de células

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application